Modulation of angiogenesis through targeting of arginyl transferase (ATE1)

Abstract

The invention provides methods and compositions for modulating angiogenesis in a subject. The methods of modulating angiogenesis in a subject include administering to the subject a modulator of N-terminal arginylation activity. The invention also provides a method of identifying such a modulator and a method of in vitro screening for modulators of N-terminal arginylation activity. Additionally, the invention provides a method of treating an angiogenesis-related disorder.

Description

RELATED APPLICATIONS

[0001] This application claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. Ser. No. 60/366,207, filed Mar. 21, 2002 and U.S. Ser. No. 60/366,218, filed Mar. 21, 2002, the entire contents of which are incorporated herein by reference.

GOVERNMENT INTERESTS

FIELD OF THE INVENTION

[0003] The invention relates generally to methods of identification of modulators of angiogenesis and more specifically to modulation of N-terminal arginy1 transferase activity.

BACKGROUND INFORMATION

[0004] Substrates of the ubiquitin (Ub)-dependent N-end rule pathway include proteins with destabilizing N-terminal residues. A set of amino acids that are destabilizing in a given cell yields a rule, called the N-end rule, which relates the in vivo half-life of a protein to the identity of its N-terminal residue. The essential component of a degradation signal called the N-degron is a destabilizing N-terminal residue of a protein. Variants of the N-end rule pathway are present in all organisms examined, from animals and plants to fungi and prokaryotes (FIG. 1A). In eukaryotes, an N-degron of a protein consists of a destabilizing N-terminal residue and an internal lysine, the latter being the site of formation of a substrate-linked multi-Ub chain. The N-end rule has a hierarchic structure (FIG. 1A). N-terminal Asn and Gln are tertiary destabilizing residues in that they function through their deamidation, by N-terminal amidohydrolases, to yield the secondary destabilizing residues Asp and Glu. The activity of N-terminal Asp and Glu requires their conjugation, by ATE1-encoded Arg-tRNA-protein transferases (R-transferases), to Arg, one of the primary destabilizing residues. The latter are recognized by the E3 (Ub ligase) components of the N-end rule pathway (FIG. 1A). In mammals, the set of destabilizing residues that function through their arginylation contains not only Asp and Glu but also Cys, which is a stabilizing (non-arginylated) residue in the yeast Saccharomyces cerevisiae. The known species of mammalian R-transferase, ATE1-1 and ATE1-2, are produced through alternative splicing of ATE1 pre-mRNA, and have the same substrate specificity as the yeast R-transferase, they arginylate N-terminal Asp or Glu, but cannot arginylate N-terminal Cys.

[0005] Angiogenesis is the growth of new blood vessels. Generally in the body, a balance of angiogenesis growth factors and angiogenesis inhibitors keeps this process of blood vessel growth under control. However, a lack or excess of either angiogenesis growth factors or angiogenesis inhibitors can cause undesired growth of blood vessels or a failure to produce blood vessels.

SUMMARY OF THE INVENTION

[0006] The present invention is based on the seminal discovery that ATE1 has an important role in angiogenesis, a role that has not been previously described.

[0007] In one embodiment, the invention is directed to a method of modulating angiogenesis in a subject. The method of the invention includes administering a modulator of N-terminal protein arginylation to a subject.

[0008] In another embodiment, the invention provides a method of identifying a modulator of N-terminal arginylation activity. The method includes providing a cell that expresses a reporter protein with an N-terminal aspartic acid, glutamic acid or cysteine residue. The half-life of the reporter protein is affected by arginylation of the N-terminal protein. The cell is contacted with one or more potential modulators of N-terminal arginylation activity. Then the level of the reporter protein expressed in the presence and absence of the modulator is measured. A change in the level of reporter protein expressed is indicative of modulation of N-terminal arginylation activity. Such a change may be an increase in expression or a decrease in expression. The level of reporter protein may be indicative of the level of protein expressed or may be indicative of the half life of the reporter. In another embodiment, the method further includes providing a second cell that expresses a second reporter protein, where the half-life of the second reporter protein is affected by N-terminal arginylation of the protein and contacting at least one potential modulator of ATE1 gene product activity with the second cell. The level of second reporter protein expressed within the second cell relative to the level of reporter protein expressed within the first cell is then determined. The invention also provides a modulator of N-terminal arginylation activity identified by the above method of the invention.

[0009] In still another embodiment, the invention provides an in vitro method of screening for modulators of N-terminal arginylation activity by providing an incubation mixture of protein substrate, ATE1 arginyl transferase source, and at least one potential modulator of ATE1 arginyl transferase activity. The level of arginylation of the peptide substrate is determined in the presence and absence of the modulator, where a change in the level of arginylation of the peptide substrate is indicative of modulation of N-terminal arginylation activity. Such a change may be an increase in expression or a decrease in level of oxidation. The invention also provides a modulator of N-terminal arginylation activity identified by the above method of the invention.

[0010] In yet another embodiment the invention is directed to a method of treating an angiogenesis-related disorder in a subject including administering a modulator of angiogenesis to the subject. The administration of the method treats the angiogenesis-related disorder in the subject.

[0011] The invention also includes a modulator identified by a method of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] FIG. 1A. N-terminal residues are indicated by single-letter abbreviations for amino acids. Ovals denote the rest of a protein substrate. Type 1 and type 2 primary destabilizing N-terminal residues, Arg, Lys, His, Phe, Leu, Trp, Tyr, and Ile, are recognized by functionally overlapping Ub ligases (E3s) that include UBRI (E3&agr;) and UBR2. N-terminal A1a, Ser and Thr are recognized by a distinct, unidentified E3.

[0013] FIG. 1B. Construction of ATE1−/−mice. Top, a map of the ˜20 kb 5′-proximal region of the ˜274 kb mouse ATE1 gene. Middle, the knockout (KO) vector. Bottom, the deletion-disruption ATE1−/− allele. Solid vertical rectangles, solid and wavy horizontal lines denote, respectively, the exons, the mouse DNA and the pBR322 DNA. The directions of transcription of NLS-lacZ (NLS-&bgr;gal), neo (neomycin), and tk (thymidine kinase) are indicated by arrows. H, HindIII; N, NcoI; X, XhoI; B, BamHI.

[0014] FIG. 1C. Northern analysis. Electrophoresed total RNA from E13.5 embryos was hybridized with CDNA probes specific for the deleted region of ATE1cDNA (nt 132-357, Ace. #AF079096) (upper panel), and with &bgr;-actin CDNA (lower panel).

[0015] FIG. 1D. Southern analysis of ATE1, using a 0.57 kb 5′-probe, a 0.45 kb 3′-probe (indicated by black rectangles in FIG. 1B, and HindIII/BamHI-cut genomic DNA from +/+, ATE1+/−, and ATE1−/− E13.5 embryos.

[0016] FIG. 2A shows quantitation of results of the stabilization of N-end rule substrates in mouse ATE1−/− cells, and oxidation-arginylation of N-terminal cysteine. ATE1+/+ and ATE1+/+ EF cells were transfected with plasmids expressing fDHFRh-UbR48-X-nsP4f, whose cleavage yielded the fDHFRh-UbR48reference protein, denoted as DHFR, and X-nsP4f test proteins (X=Met, Arg, Asp, Glu, Cys), denoted as X-nsP4. Cells were pulse-labeled for 10 min with 35S-methionine, and chased for 1 and 2 hr. For each time point, the ratio of 35S in X-nsP4f(X=Arg, Asp, Glu, Cys) to 35S in the fDHFR-UbR48 reference protein at the same time point, was plotted as the percentage of this ratio relative to that for Met-nsP4f (which bore a stabilizing N-terminal residue) at time 0. Open and closed symbols: +/+and ATE1−/− cells, respectively. &Dgr;, ▴, Met-nsP4f ; ◯, &Circlesolid;, Arg-nsP4f ; □, ▪, Asp-nsP4f ; ∇, ▾, Glu-nsP4f ; ⋄, ♦, Cys-nsP4f.

[0017] FIG. 2B shows a cell-free assay for mouse R-transferase using 3H-Arg, S105 extracts from +/+ and ATE1−/− EF cells, and unlabeled X-&bgr;gals (X=Cys, Asp, Glu, Met, Arg) and &agr;-lactalbumin as test substrates. Arginylated test substrates are indicated on the right. Asterisks indicate arginylated endogenous proteins in the extracts.

[0018] FIGS. 2C and 2D show Mouse ATE1−/− EFs were co-transfected with a plasmid expressing X-nsP4f and a plasmid expressing either wild-type S. cerevisiae ATE1 (pCDNA3yATE1) or its enzymatically impaired mutant (pCDNA3yATE1C23A). Curve designations: Met-nsP4f coexpressed with either a vector alone (open square), or yeast ATE1 (solid square), or mutant yeast ATE1 (solid black square). Cys-nsP4f. the same except for diamonds instead of squares. Asp-nsP4f : the same except for circles instead of squares.

[0019] FIG. 3 provides the primary sequence of human ATE1 arginyl transferase protein, GenBank Accession XP—052026. Alternatively spliced versions of ATE1, ATE-1p and ATE1-2p also are known: GenBank Accession numbers AAD12366 and: AAD12367 respectively.

[0020] FIG. 4 provides the nucleotide sequence of human ATE1, GenBank Accession number: XM—052026.

DETAILED DESCRIPTION OF THE INVENTION

[0021] Methods are provided herein, based on the discovery that ATE1 has an important role in angiogenesis, a role that had not been previously described. In particular, the invention provides methods for modulating angiogenisis in a subject by providing a therapeutically effective amount of a modulator of arginyl transferase activity. The invention described herein provides screening methods for modulators of N-terminal protein arginylation or the ATE1 gene product.

[0022] As used herein, the term “modulate” or “modulation” is used with regard to modulation of activity. In particular, the present invention provides modulators of arginyl transferase activity or ATE1. As used herein, modulate refers to changing the normal activity. Modulation may be inhibition of an activity or stimulation of the same.

[0023] As used herein, the term “angiogenesis” is used to refer to the growth of new blood vessels. Accordingly, an “angiogenesis-related disorder” is a disorder in which the activity of angiogenesis is altered. Such diseases may be completely caused by angiogenesis or may be exacerbated by angiogenesis activity. Angiogenesis-related disorders due to excessive angiogenesis may include, but are not limited to, cancer, tumors, rheumatoid arthritis, psoriasis, rosacea and metastasis of cancerous cells. Angiogenesis-related disorders due to insufficient angiogenesis may include, but are not limited to, coronary artery disease, stroke, ulcers and delayed wound healing.

[0024] In one embodiment, the invention provides methods for screening for modulators of N-terminal arginyl transferase activity, in which one or more potential modulators of N-terminal arginyl transferase are contacted with a first cell. The cell expresses a first reporter protein having an N-terminal aspartic acid, glutamic acid or cysteine residue. The level of said first reporter protein present is then determined in the cell either directly or through an indirect means. The level of reporter protein may be indicative of the level of protein expressed or may be indicative of the half life of the reporter. In another embodiment of the invention, the expression of the reporter protein is inducible.

[0025] The reporter protein is selected such that it has a relatively short half-life in the cell. Generally, the reporter protein has a half-life in the first cell of less than about an hour in the absence of a modulator. The reporter protein can have a half-life in the first cell of less than about 10 minutes in the absence of the modulator.

[0026] In one embodiment of the invention, the reporter protein is expressed as a cleavable fusion protein. The cleavable fusion protein can have an ubiquitin domain functionally linked to the reporter protein. In an appropriate cell, the ubiquitin domain is rapidly cleaved by one of several deubiquitylating enzymes.

[0027] In yet another embodiment of the invention, the screening methods described can be accomplished in a variety of cells, including in a cultured mammalian cell, a yeast cell or a bacterial cell.

[0028] The first type of screen for inhibitors of ATE1-mediated N-terminal arginylation can be carried in the setting of either mammalian cells in culture or yeast (S. cerevisiae) cells in culture. Note that, at least in mammalian cells and yeast, the ATE1-encoded R-transferases are solely responsible for N-terminal arginylation. The logic of either yeast- or mammalian cells-based screens is essentially the same. The advantage of a yeast-based screen is the ease of handling and analyzing yeast cell cultures; the disadvantage is that potential inhibitors of R-transferase that would cross the plasma membrane of mammalian cells may be incapable of gaining entry into yeast cells, given substantial differences in the permeability (and transport) properties of the plasma membrane between yeast and mammals. A mammalian cells-based screen is preferred, since the sought inhibitors would be intended for use in mammals. The screen: a mammalian (mouse or human) cell line is set up that expresses a short-lived reporter whose ubiquitin-dependent degradation by the N-end rule pathway involves N-terminal arginylation. Such a reporter would be a protein with either a genetically selectable or “screenable” (visually detectable) influence on the test cell culture.

[0029] A number of classes of reporter proteins are suitable for use with the methods of the invention. For example, the reporter protein can be a genetically selectable marker protein, and the relative level of the reporter protein in the presence and absence of a modulator can accomplished indirectly through a selective genetic screen which requires the presence of said reporter protein for survival of said first cell. In such an example, a modulator which inhibits the arginyl transferase activity would therefore lengthen the half-life of the reporter protein. For example, the selectable marker protein can be an antibiotic resistance protein. In one such example, the reporter protein is designed to be short-lived in a cell, the cell will be relatively sensitive to the relevant antibiotic. By contrast, if the protein is made long-lived in vivo, for example through the inhibition of a proteolytic pathway, and more specifically through inhibition of the arginyl transferase activity, that normally destroys this protein, its steady-state level would, by definition, increase, and the cell would become resistant to the same dose of antibiotic. This readout would enable a selection-based screen. A number of reporter proteins that confer antibiotic resistance are known to those skilled in the art.

[0030] Detection of the relative abundance of the reporter protein also can be accomplished by more direct means. For example, the reporter protein can be a screenable reporter protein. Such proteins may include, but are not limited to Green Fluorescent Protein (GFP) and E. coli &bgr;-galactosidase (&bgr;gal). A number of fluorescent proteins are known to those of skill in the art. These proteins, if expressed in a cell, can be detected either through their fluorescence (GFP) or through their enzymatic activity (&bgr;gal). The suitable reporter protein can-be expressed in the cell type used for the assay and has sufficient fluorescence intensity to be detected within the cell at the appropriate concentrations. Making a reporter of this class short-lived in vivo would strongly diminish its steady-state level in a cell. If degradation of such a short-lived reporter is inhibited, its steady-state level will rise, enabling the detection of reporter. The level of protein present can be determined using fluorescence detection, for example, using a fluorometer or fluorescence microscope. The relative amount of fluorescence can be compared between cells treated with a potential modulator versus no treatment. Similarly, the reporter protein can be a light-generating protein, for example, luciferase. The amount of light produced can be measured and compared in cells treated with a modulator and in untreated cells.

[0031] The level of reporter protein present can also be determined enzymatically. For example, enzymes capable of making a calorimetric change in a substrate, can be detected indirectly. One such protein, E. coli &bgr;-galactosidase (&bgr;gal), can be detected through a colorimetric change it causes in the substrate X-gal (5-bromo-4-chloro-3-indolyl-&bgr;-Dgalactosidase). Making a reporter of this class short-lived in vivo would strongly diminish its steady-state level in a cell. If degradation of such a short-lived reporter is inhibited, its steady-state level will rise, enabling the detection of the reporter protein (through an enzymatic reaction).

[0032] Other reporter protein systems are known to one of skill in the art and can be applied to the methods of the invention. As will be apparent to one of skill in the art, the invention is not limited to those currently known, but can also be extended to newly discovered reporter protein systems.

[0033] The invention also provides modulators of N-terminal arginyl transferase activity. In summary, the invention provides methods for identifying modulators of angiogenesis that operate by altering the enzymatic activity of the N-terminal arginylation of a polypeptide.

[0034] According to another embodiment of the invention, the screening methods can include additional features, including contacting the potential modulators of angiogenesis with a second cell, wherein the second cell expresses a second reporter protein having an N-terminal arginine residue and determining the level of expression of the second reporter protein relative to said first reporter protein. These settings serve as negative-controls for those in which a reporter protein contains a N-terminal aspartic acid, glutamic acid or cysteine residue. According to the invention, the second cell can be the same cell as the first cell (i.e., a cell expressing both the first reporter protein and the second reporter protein) or can be a different cell (i.e., one not expressing the first reporter protein). Such a screening method allows for the selection of modulators specific for the N-terminal arginylation activity that do not inhibit the rest of the N-end rule pathway, including subsequent protein degradation steps. According to this embodiment of the invention, a desired modulator of N-terminal arginyl transferase activity would alter the relative abundance of the N-terminal aspartic acid, glutamic acid or cysteine residue containing first reporter protein, but would not significantly alter the relative abundance of the second reporter protein having an N-terminal arginine residue. In one embodiment of such an assay system, the first reporter protein and the second reporter proteins are fluorescent proteins having distinct spectral properties.

[0035] In one embodiment of the invention, the screen is carried out with a GFP-based reporter. Mammalian cells growing in microtiter plates and expressing Asp-GFP that is designed to be N-terminally arginylated and rapidly destroyed by the N-end rule pathway, are exposed to a library of potential inhibitors of R-transferase (one tested compound per well, with different concentrations of a compound in adjacent wells). After incubation with the library of compounds, the microtiter plates are scanned by plate fluorimeter to detect wells where the levels of Asp-GFP increased. Compounds of the library that caused the increase of GFP level are then re-tested in control assays, to identify those among them that act by inhibiting N-terminal arginylation. One way to do that is to add these compounds, one at a time, to an otherwise identical mammalian cell culture that expresses Arg-GFP, a reporter identical to Asp-GFP except for Arg instead of Asp at its N-terminus. Such a reporter would be degraded by the N-end rule pathway in arginylation-independent manner. Any compound that inhibits degradation of Asp-GFP but does not significantly inhibit degradation of Arg-GFP would be, immediately, a strong candidate for a specific inhibitor of R-transferase.

[0036] Confirmation of inhibition of R-transferase may then be obtained in at least two ways: 1) in vivo, by isolating Asp-GFP from cells treated with inhibitor versus control (untreated) cells, and N-terminally sequencing Asp-GFP from these two sources, to determine whether its N-terminal arginylation was, in fact, inhibited in vivo by the compound in question; or 2) a direct enzymatic assay with purified R-transferase and test the identified compound or compounds (identified through initial screen) for inhibition of N-terminal arginylation of a model substrate in vitro.

[0037] In another embodiment of the invention, the screen is carried out with a GFP-based reporter. Mammalian cells growing in microtiter plates and expressing Asp-GFP, that is designed to be N-terminally arginylated and rapidly destroyed by the N-end rule pathway, are exposed to a library of potential inhibitors of ATE1 (one tested compound per well, with different concentrations of a compound in adjacent wells). After incubation with the library of compounds, the microtiter plates are scanned by plate fluorimeter to detect wells where the levels of Asp-GFP increased. Compounds of the library that caused the increase of GFP level are then re-tested in control assays, to identify those among them that act by inhibiting arginylation of the N-terminal aspartic acid residue. In one embodiment, the screen can differentiate between compounds that act on the arginy1 transferase versus the rest of the N-end rule pathway, including the rest of its degradation pathway (e.g., proteasome inhibition). For example, these compounds can be added, one at a time, to an otherwise identical mammalian cell culture that expresses Arg-GFP, a reporter identical to Asp-GFP except having Arg residue at its N-terminus. Such a reporter would be degraded by the N-end rule pathway in arginylation-independent manner; and therefore it would not require the action of the arginylation activity. Any compound that inhibits degradation of Asp-GFP but does not significantly inhibit degradation of Arg-GFP would be, immediately, a strong candidate for a specific inhibitor of R-transferase.

[0038] Confirmation of inhibition of ATE1 may then be obtained in at least two ways: 1) in vivo, by isolating Asp-GFP from cells treated with inhibitor versus control (untreated) cells, and N-terminally sequencing Asp-GFP from these two sources, to determine whether its N-terminal arginylation was, in fact, inhibited in vivo by the compound in question; pr 2) direct enzymatic assay with purified AET1 and test the identified compound or compounds (identified through initial screen) for inhibition of N-terminal arginylation of a model substrate in vitro.

[0039] To carry out a screen for inhibitors of N-terminal arginylation, a reporter of either class will have to be extended N-terminally with a sequence of amino acid residues known as the N-degron, a class of degradation signals (degrons) recognized by the ubiquitin-dependent N-end rule pathway of protein degradation. A particular class of N-degrons that would require N-terminal arginylation for its activity would have aspartate (Asp) as the N-terminal residue of the reporter, since asp is one of three residues arginylated by the N-end rule pathway, by R-transferase, prior to reporter's degradation. Previous extensive work by this and other laboratories made the construction of N-degron-equipped reporters a well-developed art known to researchers in the field.

[0040] A number of techniques are available to express a reporter protein having a desired N-terminal residue. Universally, translated proteins are initiated with an amino-terminal methionine residue. Processing of the protein by various peptidases can expose an internal residue as an amino-terminal residue. One such technique involves expressing a fusion protein having a ubiquitin domain and a reporter protein domain. The ubiquitin domain is rapidly cleaved from the fusion protein by a class of enzymes known as the deubiquitinylating enzymes (DUBs). This strategy is well known to one of skill in the art and is taught, for example, in references 3, 5 and 16, which are incorporated herein by reference in their entireties.

[0041] The in vitro methods for screening for modulators of angiogenesis that act through modulation of the N-terminal arginylation activity can be performed in a variety of formats. In one such method, a substrate peptide having an N-terminal aspartic acid or glutamic acid residue is incubated with one or more potential modulators of ATE1 arginyl transferase activity as well as an ATE1 arginyl transferase, and the level of arginylation of the peptide substrate is determined. The arginyl transferase can be provided as a cellular extract or can be provided as a purified enzyme. The reaction mixture can contain any necessary cofactors, for example, ATP, and arginyl-tRNA. The level of N-terminal arginylation of the peptide substrate can be determined by any suitable method, including for example, by electrophoresis, including capillary electrophoresis, by chromatography, including HPLC and TLC, by mass spectroscopy, by immunoassay. The degree or rate of N-terminal arginylation can be compared using such techniques, or combinations of techniques to determine the impact of a modulator of N-terminal arginylation activity. The type of detection used in such a scheme can be determined by one of skill in the art and will be chosen as to be compatible with the type of separation used. For example, when the technique to be used is HPLC, detection can be UV detection.

[0042] In one embodiment of the invention, the peptide substrate is immobilized, for example to the surface of a microtiter plate. In such an embodiment, the level of arginylation can be determined by reaction with an antibody that can distinguish between the substrate peptide and an arginylated form of the substrate peptide. A number of suitable detection schemes are known to one of skill in the art of immunological assays, including directly linking the antibody to a colorimetric or fluorescent moiety, or using a sandwich type assay, in which the detection means is provided by a second protein, typically an antibody which binds to the first antibody. Selective antibodies of the type necessary for such an assay can be generated by a number of techniques well known to one of skill in the art, including for example subtractive immunization.

[0043] In one embodiment, the screen would consist of purified R-transferase added to wells of microtiter plates. The R-transferase may be, but is not limited to, human or mouse. An arginylation assay is carried out in these wells either in the absence or the presence of a library of compounds (one compound per well), and the plate is screened, using either calorimetric or fluorescence-based readout, for the wells where arginylation was inhibited. The readout can be, for example, a short peptide bearing N-terminal Asp, which is arginylated by R-transferase in this in vitro assay. This peptide will have to be immobilized to bottoms of wells, a straightforward arrangement. The assay, in each well, would also contain R-transferase, ATP, Arg-tRNA and other necessary (and well known) components of arginylation reaction. A non-arginylated version of this peptide would react with a separately prepared antibody to the peptide that recognizes, among its other determinants, the peptide's (unmodified) N-terminus. Arginylation of this peptide would extinguish the recognition of peptide by this antibody, thereby providing the required readout. Other feasible variations of this assay are within the capacity of one of skill in the art.

[0044] In still another embodiment, the invention provides modulators identified by any of the methods of the invention.

[0045] In another embodiment the invention provides methods for modulating angiogenesis in a subject, comprising administering to a subject a modulator of the arginy1 transferase activity of an ATE1 gene product. In one embodiment, the subject is a mammal, such as a human or a mouse. Inhibitors of N-terminal arginy1 transferase activity can be used to treat patients, for example, who are in need of inhibited angiogenic activity, for example, those with tumors.

[0046] In still another embodiment of the invention, a method of treating an angiogenesis-related disorder is provided. The method involves administering a modulator of angiogenesis to a subject, thereby treating the angiogenesis-related disorder in the subject. Such a modulator may inhibit N-terminal protein arginylation or arginyl transferase or ATE1 gene product activity. The subject may be a mammal. The angiogenesis modulator may inhibit or stimulate angiogenesis in the subject, thereby treating the angiogenesis-related disorder. Angiogenesis-related disorders treated by this method of the invention may include, but are not limited to: cancer, tumors, rheumatoid arthritis, psoriasis, rosacea, metastasis of cancerous cells, coronary artery disease, stroke, ulcers and delayed wound healing.

[0047] In a preferred embodiment, the potential modulators are small organic compounds, that is compounds having a molecular weight of less than about 1,000. Such compounds are available from natural sources including plant, bacterial, and fungal extracts, and from techniques such as combinatorial chemistry and synthetic chemistry in general. One of skill in the art will recognize that libraries of compounds are commercially available.

[0048] The following examples are intended to illustrate but not limit the invention.

EXAMPLE 1

Generation of Ate1+/− and Ate1−/− Mice

[0049] This example describes the generation of the mice lacking the ATE1 activity. These mice serve as a model for the activity of an inhibitor of ATE1 activity (either an enzymatic inhibitor, or an inhibitor which lowers the level of expression of the ATE1 gene, for example, antisense oligonucleotides directed to the ATE1 mRNA).

[0050] Mouse ATE1 was isolated using screening, with an ATE1 cDNA fragment (nt 638-1,491), a BAC library (Genome Systems) from 129/SvJ ES mouse cells. The exon/intron organization of the first ˜20 kb of ATE1 was determined using exon-specific PCR primers to produce genomic DNA fragments flanked by exons. The targeting vector (FIG. 1B) was linearized with HindIII and electroporated into CJ7 embryonic stem (ES) cells, followed by selection and identification of the correctly targeted ATE1+/− ES cell clones with normal karyotype. Standard techniques were then used to produce chimeric and ATE1−/− mice. Phenotypes of ATE1−/− embryos were observed mainly with mice of the C57BL/6J-129SvEv (mixed) background, and confirmed in the 129SvEv (inbred) background. RT-PCR, Southern and Northern analyses, and PCR-mediated genotyping of embryos and pups were performed as described.

[0051] Heterozygous (ATE1+/−) mice were viable and apparently normal. Intercrosses of ATE1+/− mice yielded the expected frequencies of +/+ and ATE1+/− pups, but no ATE1−/− mice were recovered amongst either 954 F2-generation pups of the C57BL/6J-129SvEv (mixed) background or 267 F2-generation pups of the 129SvEv (inbred) background. Timed intercrosses of ATE1+/− mice were used to determine that ATE1−/− embryos were present at approximately the expected (25%) frequency up to ˜E13.5, but virtually no ATE1−/− embryos were recovered alive by E17. Until E12.5, ATE1−/− embryos appeared to be morphologically normal; however, their growth stopped during E13.5-E15.5. By E14.5-E15.5, ˜50% of ATE1−/− embryos were still alive, but growth-retarded. Live E14.5-E15.5 embryos were capable of opening their mouths and flexing their bodies, suggesting the absence of gross neuromuscular defects. Sections through E13.5 ATE1−/− embryos indicated the presence and apparently normal appearance of major organs, except for the phenotypes described below in Example 3.

EXAMPLE 2

Expression of Ate1- Allele

[0052] The ATE1−/− allele was marked with NLS-&bgr;-galactosidase (hereafter &bgr;gal), expressed from the ATE1 promoter (FIG. 1B). During E9.5-E12.5, the expression of ATE1 (&bgr;gal) was high in the neural tube, including the floor plate, motor neurons, and the neural fold. ATE1 was also expressed in dorsal root ganglia, sympathetic ganglia and notochord, and in neurons that regulate blood vessels; the latter examples included sympathetic trunks between midline dorsal aorta and subcardinal vein, and a ganglion near the primary head vein. ATE1 was also expressed in sharply delineated subsets of myotomal cells in each somite, in the mesonephric vesicles (kidney precursor), in the gut, in specific areas of the eye primordium, at the tips of limb buds, in the endodermal layer of the yolk sac (but not in its mesodermal layer), and in specific areas of embryonic heart, including trabeculae, endocardial cushion, aortic valve, and aorta.

EXAMPLE 3

Angiogenic Defects of Ate1−/− Mice

[0053] ATE1−/− embryos (and yolk sacs) were pale in comparison to their +/+ and ATE1+/− littermates, had thinner blood vessels and frequent edemas of the skin, with extensive apoptosis of cells in edematous regions. About 40% of live E15.5 ATE1−/− embryos looked nearly normal, except for a significant growth retardation, thinner peripheral vessels and thinner vitelline vessels. The rest (˜60%) of live E15.5 ATE1−/− embryos exhibited at least one of the following phenotypes: local hemorrhages, edemas, and abdominal ruptures. Hemorrhages, often massive, at various locations, predominantly in the abdominal cavity and the head, were a consistent feature of ATE1−/− embryos, and the likely proximal cause of their death by E15-E17. Transverse sections of hematoxylin/eosin-stained +/+ and ATE1−/− hearts of E14.5 embryos showed numerous defects. Amongst 13 ATE1−/− hearts (E13.5-E15.5) examined, ˜85% had a ventricular septal defect (VSD). The atria of many ATE1−/− hearts were abnormally thin-walled, with sparse trabeculae and a large atrial septal defect (ASD). The right atria of ATE1−/− hearts were often enlarged, resulting in twisted ventricles (data not shown). Amongst 22 ATE1−/− hearts examined (13 extensively and 9 less so), ˜90% exhibited hypoplasia of both right and left ventricular myocardium, resembling thin myocardium syndrome. The compact zone (CZ) of left ventricular myocardium was typically 2-3 cells thick, in comparison to 7-10 cells in the myocardium of +/+ littermates. Furthermore, whereas the aorta and pulmonary artery were completely separated by E13.5 in +/+ hearts, ˜70% of the examined ATE1−/− hearts (E13.5-E15.5)had persistent truncus arteriosus (PTA), with the common root of aorta and pulmonary artery straddling a large VSD. Formation of the two ventricular chambers involves proliferation and maturation of myocytes in the compact muscular layer, accompanied by trabeculation inside the chamber. The septum is formed through condensation of trabeculae at the interventricular groove, with the medial walls of expanding ventricles fusing together, growing inward, and forming the muscular portion of septum. The above defects of ATE1−/− M hearts suggest that the loss of R-transferase activity inhibits proliferation of myocardial cells. In addition, the PTA defect occurs when too few of the neural crest-derived cells populate the cardiac outflow tract, resulting in a failure to separate the common truncal outflow vessel into the aorta and pulmonary artery. Since ATE1 is highly expressed in structures produced by cells originating in the neural crest, the PTA defect of ATE1−/− hearts suggests that the R-transferase activity is also required for migration and/or differentiation of neural crest-derived myocardial cells.

[0054] Vasculogenesis, the de novo formation of blood vessels that yields the primary capillary plexus at early stages of embryogenesis, was apparently normal in E9.5 ATE1−/− embryos, as assayed by staining endothelial cells with anti-PECAM antibody. Standard procedures were used for thin sectioning and staining with hematoxylin/eosin, X-Gal, or anti-PECAM-1 antibody (clone MEC 13.3, Pharmingen). In contrast, the process of subsequent angiogenic remodeling that produces a hierarchic network of mature capillaries and larger vessels, was perturbed in the absence of ATE1, as could be seen, for example, in the vasculature of E13.5+/+ versus ATE1−/− yolk sacs. The vessels in ATE1−/− sacs often terminated prematurely, and many small vessels remained as a honeycomb-like meshwork of the primary-plexus capillaries, without angiogenic remodeling. The large collecting vessels of ATE1 −/− yolk sacs were consistently smaller than their +/+ counterparts, and ATE1−/31 microvilli were poorly developed. In addition, the angiogenesis-produced network of blood vessels that normally cross the dorsal midline and that normally sprout from intersegmental artery was suppressed in E9.5 ATE1−/− embryos. An example of impaired angiogenesis in older ATE1−/− embryos was the head's dorsal area at E13.5. This area was a major site of hemorrhages in ATE131 /− embryos. Amongst 13 extensively examined ATE1−/− embryos, only one appeared to have a normal heart; yet, similarly to other ATE1−/− embryos, it exhibited angiogenesis defects in the yolk sac, suggesting that abnormal angiogenic remodeling was not caused by the cardiogenic defects of ATE1−/− embryos. A rigorous deconvolution of causes and effects in this complex setting will require the understanding of molecular circuits involved.

[0055] Increased apoptosis, detected using the TUNEL assay, was found in the edematous area of E13.5 ATE1−/− embryo. The TUNEL assay was performed using a kit (Roche) and fluorescein-dUTP.

[0056] This example clearly illustrates the importance of the ATE1 gene to the process of angiogenesis. The clear evidence that mice lacking the ATE1 gene shows that inhibitors of ATE1 will also impact angiogenesis in an animal.

EXAMPLE 4

Arginyl Transferase Reactions

[0057] For R-transferase assays (FIG. 2B), Ub-X-&bgr;gal proteins were purified from E. coli carrying pKKUbX&bgr;gal plasmids. The R-transferase reaction (50 ml) contained S105 supernatant (0.5 mg of protein per ml) from either EF cells or whole embryos, prepared as described (30), Ub-X-&bgr;gal or &agr;-lactalbumin (0.2 mg/ml), E. coli tRNA (1 mg/ml), E. coli aminoacyl-tRNA synthetases (50 mg/ml), puromycin (0.2 mM), bestatin (0.15 mM), 5 mM MG 132 (proteasome inhibitor), 0.4 mM Lys-Ala dipeptide (inhibitor of post-arginylation steps in the N-end rule pathway), 1 mM ATP, 10 mM creatine phosphate, 0.1 M KCl, 5 mM MgCl2, 50 mM &bgr;-mercaptoethanol, 50 mM Tris-HCl (pH 8.0) and 0.3 mM 3H-arginine (New England Nuclear). The reaction mixture was incubated for 3 hr (2 hr with embryo extracts) at 37° C. A 20 ml sample was precipitated with 10% TCA, and analyzed by SDS12% PAGE and fluorography.

[0058] To measure the N-terminal arginylation directly, either purified Ub-X-&bgr;gal proteins (X=Met, Arg, Glu, Cys) or purified human a-lactalbumin (bearing N-terminal Glu) were added to +/+ and ATE1−/− EF cell extracts supplemented with ATP, total E. coli tRNA and a mixture of E. coli aminoacyl-tRNA synthetases. SDS-PAGE and fluorography were used to detect covalent conjugation of 3H-Arg to test proteins in these extracts (FIG. 2B). Ub-X-&bgr;gals are rapidly deubiquitylated in vivo and in cell-free extracts, yielding X-&bgr;gal test proteins. As expected, Asp-&bgr;gal, Glu-&bgr;gal and &agr;-lactalbumin were arginylated in the extracts from +/+ EF cells, whereas Arg-&bgr;gal and Met-&bgr;gal, bearing a primary destabilizing and a stabilizing N-terminal residue, respectively, were not arginylated (FIG. 2B). Crucially, no arginylation of Asp-&bgr;gal, Glu-&bgr;gal and &agr;-lactalbumin could be detected in ATE1−/− EF extracts (FIG. 2B), even after prolonged fluorographic exposures. Identical results were obtained with extracts from +/+ and ATE1−/− embryos. In addition to being consistent with the conclusions from pulse-chase analyses in EF cells, these findings confirmed the absence of R-transferase activity from ATE1−/− embryos.

EXAMPLE 5

Assays in Mouse Embryonic Fibroblasts

[0059] Primary mouse EFs were established from E13.5 ATE1−/− and littermate +/+ embryos as described, and immortalized to increase transfection efficiency. Cells were transiently transfected with pcDNA3flagDHFRhaUbXnsP4flag, which expressed fDHFRhUbR48-X-nsP4f from the PCMV promoter. Cells were labeled with 35S-EXPRESS (New England Nuclear) for 10 min at 37° C., followed by a chase for 0, 1, and 2 hr in the presence of cycloheximide, preparation of extracts, precipitation with anti-flag antibody, SDS-10% PAGE, autoradiography, and quantitation using Phosphorlmager. In other pulse-chases, ATE1−/−EFs were co-transfected with a plasmid expressing X-nsP4f (fDHFRh-UbR48-XnsP4f) and either pCDNA3yATE1, expressing S. cerevisiae ATE 1, or pCDNA3yATE1C23A (derived from a plasmid supplied by Dr. C. Pickart, Johns Hopkins University), which expressed ATE1C23SA, bearing Cys→Ala mutation at position 23.

[0060] To examine the in vivo degradation of N-end rule substrates in ATE1−/− cells, immortalized embryonic fibroblast (EF) cell lines were established from ATE1−/− and littermate +/+ embryos. The EFs were transiently transfected with plasmids that expressed X-nsP4f, a set of otherwise identical 69K flag-tagged Sindbis virus RNA polymerase proteins bearing different N-terminal residues (FIG. 1A). X-nsP4f proteins were expressed as parts of fDHFRh-UbR48-X-nsP4f fusions, the UPR (Ub/protein/reference) constructs, in which the reference moiety fDHFRhUbR48 contained an epitope-tagged mouse dihydrofolate reductase (DHFR). DHFRh-UbR48-X-nsP4f is cotranslationally cleaved by deubiquitylating enzymes (DUBs) at the UbR48-X junction, yielding the long-lived fDHFRh-UbR48 reference protein and a test protein X-nsP4f. Through the presence of a “built-in” reference protein, the UPR technique increases the accuracy of pulse-chase assays, and in addition allows the detection of a test protein's degradation during the pulse. As expected, R-transferase substrates were short-lived in +/+ EF cells: more than 90% of pulse-labeled Asp-nsP4f and Glu-nsP4f were degraded by 2 hr of chase. In contrast, both Asp-nsP4f and Glu-nsP4f were completely stabilized in ATE1−/− cells, whereas Arg-nsP4f, bearing a primary (arginylation-independent) destabilizing N-terminal residue, remained short-lived in these cells. Strikingly, although the mouse ATE1−/− encoded R-transferases cannot arginylate N-terminal Cys, the normally short-lived Cys-nsP4 f also became long-lived in ATE1−/− EF cells, indicating that ATE1 is required for the arginylation of N-terminal Cys, through a mechanism determined by the inventors to involve a catalytic oxidation of N-terminal cysteine residues.

EXAMPLE 6

Gene Circuits Involving ATE1

[0061] To begin a search for mouse genes whose expression is significantly altered in the ATE1−/− background, RT-PCR and Northern analyses were carried out with total RNA from +/+ and littermate ATE1−/− embryos proper, their yolk sacs, and their hearts, using mouse cDNA probes specific for genes that encode the following proteins: NTAN1, UBR1, UBR2 (components of the N-end rule pathway); ehand, ICAM2, GATA6, Nfarc1, dHand, NF1, RXR&agr;, FOG2, GATA4, MEF2c, Neuropilin 1, TEF1, N-myc, RAR&agr;, ErbB2 (proteins whose functions include heart development); TIE1, TIE2, FLK1, FLK2, FLT1, FLT4, &bgr;H1, GATA1, I1-3R, CD34, VEGF, VEGF-B, VEGF-C, VEGF-D, ANG1, ANG2, ANG3, EfnB1, EfnB2, EfnA1, EphB2 (proteins whose functions include vascular development). No significant differences were detected in the expression of these genes between the ATE1−/− and +/+ genetic backgrounds, making it more likely that the absence of ATE1 impacted a previously undescribed circuit.

[0062] The N-end rule is implicated in a variety of physiological processes, including angiogenesis. Mice lacking the gene ATE1 were shown to have extensive defects in angiogenic development. Because of the importance of the arginylation pathway to angiogenesis, inhibitors of the N-termninal arginyl transferase activity can be used as anti-angiogenic compounds for the treatment of tumors, and particularly of solid tumors.

[0063] Recent studies have identified the mammalian Met-aminopeptidase MetAP2 as the target of fumagillin and related inhibitors of angiogenesis. Upon inhibition of MetAP2, some intracellular proteins partially retain their N-terminal Met residues. The N-terminal Met-Cys bond (but neither Met-Asp nor Met-Glu) can be cleaved by MetAP2. The results suggest that metabolic stabilization of an arginylation-dependent N-end rule substrate(s) in mouse ATE1−/− cells causes angiogenic and cardiogenic defects. Thus, one possibility is that fumagillin and related drugs may act by partially inhibiting the N-terminal Met-Cys cleavage and thereby partially stabilizing an otherwise short-lived repressor(s) of angiogenesis that bears a Cys-containing N-degron. If the repressor's half-life is normally short enough, even a small fraction of repressor molecules that retain Met-Cys and are, therefore, long-lived, would yield a strong increase in the repressor's steady-state level, thereby possibly accounting for the finding that even a partial inhibition of MetAP2 is sufficient to block proliferation of endothelial cells. Likewise, inhibition of the cysteine oxidase pathway and/or arginylation dependent pathway also is likely to block such proliferation.

[0064] References:

[0065] 1. A. Bachmair, D. Finley, A. Varshavsky, Science 234, 179-186(1986).

[0066] 2. A. Varshavsky, Proc. Natl. Acad. Sci. USA 93, 12142-12149(1996).

[0067] 3. Y. T. Kwon, Z.-X. Xia, I. V. Davydov, S. H. Lecker, A. Varshavsky, Mol. Cell. Biol. 21, 8007-8021 (2001).

[0068] 4. A. Hershko, A. Ciechanover, A. Varshavsky, Nature Med. 10, 1073-1081(2000).

[0069] 5. H. Rao, F. Uhlmann, K. Nasmyth, A. Varshavsky, Nature 410, 955-960(2001).

[0070] 6. G. C. Turner, F. Du, A. Varshavsky, Nature 405, 579-583(Jun. 1, 2000.)

[0071] 7. Y. T. Kwon et al., Mol. Cell. Biol. 20, 4135-4148(2000June 2000).

[0072] 8. I. V. Davydov, A. Varshavsky, J. Biol. Chem. 275, 22931-22941(2000).

[0073] 9. Y. T. Kwon, A. S. Kashina, A. Varshavsky, Mol. Cell. Biol. 19, 182-193(1999 January 1999).

[0074] 10. C. Pickart, Annu. Rev. Biochem. 70, 503-533(2001).

[0075] 11. D. K. Gonda et al., J. Biol. Chem. 264,16700-16712(1989).

[0076] 12. M. Jaber et al., Proc. Natl. Acad. Sci. USA 93, 12794-12979(1996).

[0077] 13. D. Srivastava, Annu. Rev. Physiol. 63, 451-469(2001).

[0078] 14. T. L. Creazzo, E. G. Robert, L. Leatherbury, S. J. Conway, M. L. Kirby, Annu. Rev. Physiol. 60, 267-286(1998).

[0079] 15. T. Suzuki, A. Varshavsky, EMBO J. 18, 6017-6026(1999 Nov. 1, 1999).

[0080] 16. G. C. Turner, A. Varshavsky, Science 289, 2117-2120(2000).

[0081] 17. T. Tetaz, J. R. Morrison, J. Andreaou, N. H. Fidge, Biochem. Int. 22, 561-566(1990). p0 18. T. Yagi, H. Kagamiyama, M. Nozaki, Biochem. Biophys. Res. Comm. 90, 447-452(1979).

[0082] 19. F. M. Ausubel et al., Eds., Current Protocols in Molecular Biology. (WileyInterscience, New York, 2000).

[0083] 20. J. Li, C. M. Pickart, Biochemistry 34, 15829-15837(1995).

[0084] 21. H. Kaiji, G. D. Novelli, A. Kaiji, Biochim. Biophys. Acta 76, 474-479(1963).

[0085] 22. R. L. Soffer, in Transfer RNA: Biological Aspects. D. Soll, J. Abelson, P. R. Schimmel, Eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1980) pp. 493-505.

[0086] 23. S. Qusti et al., Cell Biol. Toxicol. 16, 243-255(2000).

[0087] 24. Y. M. Wang, N. A. Ingoglia, Neurochem. Res. 22, 1453-1459(1997).

[0088] 25. S. Hauf, I. C. Waizenegger, J.-M. Peters, Science 293, 1320-1323(2001).

[0089] 26. E. C. Griffith et al., Chem. Biol. 4, 461-471(1997).

[0090] 27. N. Sin et al., Proc. Natl. Acad. Sci. USA 94, 6099-7103(1997).

[0091] 28. R. K. Bruick, S. L. McKnight, Science 294, 1337-1340(2001).

[0092] 29. Y. T. Kwon et al., Proc. Natl. Acad. Sci. USA 95, 7898-7903(1998).

[0093] 30. K. Takao, K. Samejima, Biol. Pharm. Bull. 22, 1007-1009(1999).

[0094] 31. Q. Ma, Z. Chen, I. del Barco Barrantes, J. L. de la Pompa, D. J. Anderson, Neuron 20, 469-482(1998).

[0095] Although the invention has been described with reference to the above examples, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.

Claims

1. A method of modulating angiogenesis in a subject, comprising administering to a subject a modulator of N-terminal protein arginylation, thereby modulating angiogenesis in the subject.

2. The method of claim 1, wherein the modulator inhibits ATE1 gene product activity.

3. The method of claim 1, wherein the subject is a mammal.

4. A method of identifying a modulator of N-terminal arginylation activity, comprising:

a) providing a cell that expresses a reporter protein with an N-terminal aspartic acid, glutamic acid or cysteine residue, wherein the half-life of the reporter protein is affected by arginylation of the N-terminal protein;

b) contacting at least one potential modulator with the cell; and

c) measuring the level of the reporter protein expressed in the presence and absence of the modulator, wherein a change in the level of reporter protein expressed is indicative of modulation of N-terminal arginylation activity.

5. The method of claim 4, wherein the cell is a cultured mammalian cell.

6. The method of claim 4, wherein the cell is a yeast cell.

7. The method of claim 4, wherein the cell is a bacterial cell.

8. The method of claim 4, wherein the reporter protein is expressed as a cleavable fusion protein comprising a reporter protein and a ubiquitin domain functionally linked to the reporter protein, wherein the reporter protein comprises an N-terminal aspartic acid, glutamic acid or cysteine.

9. The method of claim 4, wherein the reporter protein comprises a selectable marker protein, and the measuring comprises a selective genetic screen.

10. The method of claim 9, wherein the selectable marker protein is an antibiotic resistance protein.

11. The method of claim 4, wherein the measuring comprises fluorescence detection of the reporter protein.

12. The method of claim 4, wherein the reporter portion comprises a fluorescent protein.

13. The method of claim 12, wherein the fluorescent protein is Aequorea green fluorescent protein.

14. The method of claim 4, wherein the reporter portion comprises a light-generating protein.

15. The method of claim 13, wherein the light-generating protein is luciferase.

16. The method of claim 4, wherein the reporter portion comprises an enzyme.

17. The method of claim 16, wherein the enzyme is beta-galactosidase.

18. The method of claim 4, wherein the expression of the reporter protein is inducible.

19. The method of claim 4, wherein the reporter protein has a half-life in the first cell of less than about an hour in the absence of a modulator.

20. The method of claim 4, wherein the reporter protein has a half-life in the first cell of less than about 10 minutes in the absence of a modulator.

21. The method of claim 4, wherein the change in the level of reporter protein expressed is increased expression.

22. The method of claim 4, further comprising:

d) providing a second cell that expresses a second reporter protein, where the half-life of the second reporter protein is affected by N-terminal arginylation of the protein;

e) contacting at least one potential modulator of ATE1 gene product activity with the second cell; and

f) measuring the level of second reporter protein expressed within the second cell relative to the level of reporter protein expressed within the first cell.

23. The method of claim 22, wherein the cell in step a) and the second cell are the same cell.

24. A modulator of N-terminal arginylation activity identified by the method of claim 4.

25. The modulator of claim 24, wherein the modulator functions by modulating ATE1 gene activity.

26. The modulator of claim 24, wherein the modulator functions by modulating ATE1 gene product activity.

27. The method of claim 4, wherein the modulator of N-terminal arginylation activity also modulates angiogenesis.

28. A method of modulating angiogenesis in a subject, comprising administration of a modulator identified by the method of claim 4.

29. An in vitro method of screening for modulators of N-terminal arginylation activity, comprising:

a) providing an incubation mixture comprising protein substrate, ATE1 arginy1 transferase source, and at least one potential modulator of ATE1 arginy1 transferase activity; and

b) determining the level of arginylation of the peptide substrate in the presence and absence of the modulator, wherein a change in the level of arginylation of the peptide substrate is indicative of modulation of N-terminal arginylation activity.

30. The method of claim 29, wherein the protein substrate further comprising an N-terminal amino acid selected from the group consisting of aspartic acid and glutamic acid.

31. The method of claim 29, wherein the ATE1 arginyl transferase source is a cellular extract.

32. The method of claim 29, wherein the ATE1 arginyl transferase source is a purified enzyme.

33. The method of claim 29, wherein the incubation mixture further comprises ATP and arginyl-tRNA.

34. The method of claim 29, wherein said peptide substrate is immobilized to a solid surface.

35. The method of claim 29, wherein said solid surface comprises a microtiter plate.

36. The method of claim 29, wherein the determining of the level of arginylation comprises electrophoresis, chromatography, mass spectrometry or imunoassay.

37. The method of claim 29, wherein the determining of the level of arginylation comprises reaction with an antibody that distinguishes between the substrate peptide and an arginylated substrate peptide.

38. The method of claim 29, wherein the modulator of N-terminal arginylation activity also modulates angiogenesis.

39. The method of claim 29, wherein the change in the level of arginylation of the peptide substrate is increased arginylation.

40. A modulator of N-terminal arginylation activity identified by the method of claim 29.

41. A method of modulating angiogenesis in a subject, comprising administration of a modulator identified by the method of claim 28.

42. A method of treating an angiogenesis-related disorder in a subject comprising administering to a subject a modulator of angiogenesis, thereby treating the angiogenesis-related disorder in the subject.

43. The method of claim 42, wherein the modulator inhibits N-terminal protein arginylation.

44. The method of claim 43, wherein the modulator inhibits ATE1 gene product activity.

45. The method of claim 42, wherein the subject is a mammal.

46. The method of claim 42, wherein the modulator of angiogenesis inhibits angiogenesis in the subject.

45. The method of claim 42, wherein the angiogenesis-related disorder is cancer, tumors, rheumatoid arthritis, psoriasis or metastasis of cancerous cells in the subject.

48. The method of claim 42, wherein the modulator of angiogenesis stimulates angiogenesis in the subject.

49. The method of claim 42, wherein the angiogenesis-related disorder is coronary artery disease, stroke or delayed wound healing.